tbuckley/cabot-search huggingface dataset:
Identification of the familial cylindromatosis tumour-suppressor gene
Authors: Graham R. Bignell, William Warren, Sheila Seal, Meiko Takahashi, Elizabeth Rapley, Rita Barfoot, Helen Green, Carolanne Brown, Patrick J. Biggs, Sunil R. Lakhani, Christopher Jones, Juliana Hansen, Edward Blair, Benedikt Hofmann, Reiner Siebert, Gwen Turner, D. Gareth Evans, Connie Schrander-Stumpel, Frits A. Beemer, Ans van den Ouweland, Dicky Halley, Bertrand Delpech, Mark G. Cleveland, Irene Leigh, Jaakko Leisti, Sonja Rasmussen, Margaret R. Wallace, Christiane Fenske, Piu Banerjee, Naoki Oiso, Ranbir Chaggar, Samantha Merrett, Niamh Leonard, Marcel Huber, Daniel Hohl, Pam Chapman, John Burn, Sally Swift, Anna Smith, Alan Ashworth, Michael R. Stratton
Journal: Nature Genetics (2000)
microRNAs as clinical biomarkers for lung cancer classification
Authors: Tina B. Edmonston, Michal Kushnir, Ranit Aharonov, Gila Lithwick Yanai, Hila Benjamin, Marluce Bibbo, Craig Thurm, Laurie Horowitz, Yajue Huang, Shlomit Gilad, Ayelet Chajut
Journal: Clinical Cancer Research (2010)

Abstract Background: Lung cancers have been traditionally subdivided into two main groups: neuroendocrine and non-small cell lung cancer (NSCLC). In 20-30% of lung cancer cases it is difficult to make a definitive diagnosis of the tumor subtype based on the cytological specimen (e.g., fine-needle aspirates). In general, the classification of lung cancers poses a diagnostic challenge and there is lack of standardized techniques for cancer sub-typing. For patients with lung carcinoma, accurate determination of tumor type significantly influences treatment decision. MicroRNA expression profiling is a promising new strategy for the precise subclassification of lung cancers. We have previously described a microRNA-based assay which accurately differentiates between squamous and non-squamous NSCLC in FFPE derived from resections as well as from cytological samples. We have also used microRNA microarray data generated from over a hundred formalin-fixed, paraffin-embedded (FFPE) samples of primary lung cancer, to identify microRNA expression profiles that differ significantly for various sub-types of lung cancer samples. Based on these findings, we present here the development of a microRNA-based assay that is able to differentiate primary lung cancers into neuroendocrine vs. NSCLC and then further sub-classify NSCLC into squamous vs. non-squamous and neuroendocrine into SCLC vs. carcinoid using pathology and cytology samples. Methods: FFPE of resections and cell blocks from different histological subtypes of lung cancer, taken from primary lung cancer resection or pre-operative diagnostic procedures, were collected. High-quality RNA, including the well-preserved microRNA fraction, was extracted from the samples using proprietary protocols. Expression levels of potential microRNA biomarkers were profiled using a sensitive and specific qRT-PCR platform. Results: We find that combinations of small numbers of microRNAs can successfully differentiate between the four different histological types of lung cancers, with very high sensitivity and specificity. These microRNAs are able to subclassify lung cancer FFPE samples derived from pathological and cytological samples. Conclusion: We identified microRNAs that represent excellent biomarkers for the classification of lung primary cancers. These findings are the basis for the development of a simple and reliable qRT-PCR based diagnostic assay which will offer an accurate and standardized tool for primary lung cancer pathological and cytological samples, including those that presently fail pathological evaluation.
A novel von Willebrand disease–causing mutation (Arg273Trp) in the von Willebrand factor propeptide that results in defective multimerization and secretion
Authors: Simon Allen, Adel M. Abuzenadah, Joanna Hinks, Joanna L. Blagg, Turkiz Gursel, Jørgen Ingerslev, Anne C. Goodeve, Ian R. Peake, Martina E. Daly
Journal: Blood (2000)
ON THE SIGNIFICANCE OF THE NORMAL ELECTROCARDIOGRAM IN OLD AGE
Authors: T T FOX
Journal: Annals of Internal Medicine (1949)

Article1 July 1949ON THE SIGNIFICANCE OF THE NORMAL ELECTROCARDIOGRAM IN OLD AGETHEODORE T. FOX, M.D.THEODORE T. FOX, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-31-1-120 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptIn 1939 a group of 300 ambulatory inmates of the Home and Hospital of the Daughters of Israel, an institution for the care of the aged, was subjected to a cardiovascular study, and the results, stressing particularly the electrocardiographic changes in senescence, were reported in the literature.1Of the 300 inmates 200 had abnormal electrocardiograms and 100 cases had normal tracings. A normal tracing was considerednormalby the usual standards: no allowances were made for certain deviations "frequently" (?) observed in older people. It was concluded that the incidence of abnormal electrocardiograms increases with age and is fairly parallel...Bibliography1. FOXKLEMENTSMANDEL TTJEE: Electrocardiographic changes in old age, Ann. Int. Med., 1942, xvii, 236-246. Google Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: New York, N. Y.*Received for publication February 28, 1948.From the medical service of the Home and Hospital of the Daughters of Israel, New York, N. Y. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byThe effect of aging on the electrocardiographic findings in the elderly — a 10-year longitudinal study: the Koganei studyAn Electrocardiographic Survey of the AgedElectrocardiographic findings in the agedElectrocardiographic Findings at Rest, during and after Exercise in Healthy Old Men Compared with Young MenDas Herzvolumen und die Leistungsfähigkeit bei 60–75 jährigen gesunden MännernErfarenheter vid elektrochockbehandling av åldringar 1 July 1949Volume 31, Issue 1Page: 120-124KeywordsAgingElectrocardiographyMedical services ePublished: 1 December 2008 Issue Published: 1 July 1949 PDF downloadLoading ...
The effects of rosiglitazone therapy in early stage breast cancer
Authors: Lisa D. Yee, Nita Williams, Ping Wen, Donn C. Young, Joanne Lester, Maria V. Johnson, William B. Farrar, Michael J. Walker, Stephen P. Povoski, Saul Suster, Charis Eng
Journal: Cancer Research (2006)

430  Peroxisome proliferator-activated receptor gamma (PPARγ) is a steroid nuclear receptor that is activated by natural compounds such as specific fatty acids as well as synthetic drugs such as the thiazolidinedione antidiabetic agents. Expressed in normal and malignant mammary epithelial cells, activation of PPARγ is associated with antiproliferative and differentiating effects on human breast cancer cells in vitro and in vivo. To test the hypothesis that PPARγ ligand therapy might inhibit tumor growth and progression in human breast cancer, we conducted a Phase I clinical trial of short-term (2 to 6 weeks) treatment with the thiazolidinedione rosiglitazone in women with early stage breast cancer. Administered between the time of diagnostic biopsy and definitive surgery, rosiglitazone (8 mg/day) was well-tolerated by the 38 study subjects, without serious adverse events. Treatment with rosiglitazone resulted in increased serum adiponectin (p
Abstract CT113: A phase III, multicenter, randomized study evaluating the efficacy and safety and efficacy of erythrocyte encapsulated l-asparaginase (Ery001) versus native l-asparaginase (L-asp) in combination with COOPRALL regimen in patients with first relapse of acut
Authors: Yves Bertrand, Andre Baruchel, Xavier Thomas, Nicolas Blin, Emmanuelle Tavernier, Yves Perel, Norbert Vey, Virginie Gandemer, Iman ElHariry, Yann Godfrin
Journal: Cancer Research (2015)

Abstract Asparaginases are a cornerstone in the treatment of ALL, but their utility is limited by toxicities including hypersensitivity. ERY001 improves pharmacokinetics and tolerability, while maintaining circulating asparaginase (ASPA) activity due to the protective barrier of the erythrocyte membrane. This phase III study enrolled pts with primary relapsed/refractory Ph- ALL. The co-primary endpoints were the duration of ASPA activity equal or greater than 100IU/L and the incidence of ASPA hypersensitivity during induction. Patients, aged 1-55 years, without prior ASPA hypersensitivity were randomized to ERY001 (150 IU/kg) or L-ASP(10.000IU/m2) in combination with COOPRALL. The patients with prior ASPA hypersensitivity received ERY001. ERY001 significantly reduced the incidence of ASPA hypersensitivity (0% vs 43%; p100IU/l significantly longer than L-ASP (20.5±5.2 vs 9.2±7.5 days; p&amp;lt;0.001). CR and clotting parameters were also significantly improved in the ERY001 arm. Other adverse events were generally similar in. One-year OS was 77% in the ERY001 arm vs 68% in L-ASP arm. ASPA activity was not reduced in hypersensitive patients. These highly encouraging results show that ERY001 is a suitable option for patients with relapsed ALL maintaining ASPA efficacy with improved tolerability. Citation Format: Yves Bertrand, Andre Baruchel, Xavier Thomas, Nicolas Blin, Emmanuelle Tavernier, Yves Perel, Norbert Vey, Virginie Gandemer, Iman ElHariry, Yann Godfrin. A phase III, multicenter, randomized study evaluating the efficacy and safety and efficacy of erythrocyte encapsulated l-asparaginase (Ery001) versus native l-asparaginase (L-asp) in combination with COOPRALL regimen in patients with first relapse of acut [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr CT113. doi:10.1158/1538-7445.AM2015-CT113
Lost in a Dark Wood
Authors: L J Hergott
Journal: JAMA (2001)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
In-stent restenosis in small coronary arteries
Authors: Carlo Briguori, Cristiano Sarais, Paolo Pagnotta, Francesco Liistro, Matteo Montorfano, Alaide Chieffo, Fabio Sgura, Nicola Corvaja, Remo Albiero, Goran Stankovic, Costantinos Toutoutzas, Erminio Bonizzoni, Carlo Di Mario, Antonio Colombo
Journal: Journal of the American College of Cardiology (2002)
Comparing non-invasive cardiovascular risk assessment tools in COPD patients: Validation with CV events
Authors: Jorge Zagaceta, Javier Zulueta, Gorka Bastarrika, Inmaculada Colina, Arantza Campo, Ana Belen Alcaide, Pablo Sánchez, Juan Bertó, Pilar Rivera, Bartolome Celli, Juan Pablo de Torres
Journal: European Respiratory Journal (2014)

Rationale: COPD is an independent risk factor for coronary artery disease (CAD) and cardiovascular (CV) disease is one of the main causes of death in COPD patients.

Objectives: Compare the different non-invasive CV risk tools in COPD patients.

Methods: COPD patients of all degree of severity were prospectively recruited from January 2001 to August 2012. At enrollment we measured: lipid profile, CRP, urine albumine/creatinine ratio, Framingham, SCORE, BODE and its components, coronary artery calcium (CAC) and epicardial adipose tissue (EAT). Their predictive power of CV events was then compared.

Results: Patients characteristics are shown in Table 1

![Figure][1] 



.The median follow-up was 34 months (IQR: 7.8 to 72 months) with a total of 84 recorded CV events: 20 (24%) AMI, 19 (21%) ischemic heart disease/angina, 28 (34%) peripheral artery disease and 18 (21%) strokes.Twelve deaths ocurred, 3 (25%) from CV disease. Table 2 shows the univariate analysis exploring the independent association of each of the risk assessment tools with the ocurrence of CV event. Table 3 shows the multivariate analysis identifying those with the best predictive power. The under area curve (UAC) were: CAC (c statistic = 0.65), Framingham (c stat=0.602), SCORE (c stat=0.55), EAT (c stat=0.52) and 6MWD (c stat=0.65).

Conclusions: In this population of well-characterised COPD patients, CAC and the 6MWD were the best independent predictors of CV events.

 [1]: pending:yes
Bundled Approaches for Surgical Site Infection Prevention
Authors: Preeti N. Malani
Journal: JAMA (2015)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 900: Computing tumor growth rate across pre- and post-treatment periods uncovers anti-tumor activity in patients treated by a pan-CDK inhibitor (BAY1000394)
Authors: Antoine Hollebecque, Charles Ferte, Gerard Nitenberg, Mathieu Felices, Alexandre Durand-Salmon, Matthias Ocker, Jean-Charles Soria
Journal: Cancer Research (2014)

Abstract Background: Recent studies suggest that tumor shrinkage as measured by RECIST 1.1 criteria may not be adequate to assess early signs of anti-tumor activity in phase I trials. The value of Tumor Growth Rate (TGR) evaluation in this context has been suggested. Methods: We analyzed the TGR of solid tumors from patients prospectively enrolled in a dose-escalation phase I trial investigating the pan-CDK inhibitor BAY1000394 on a 3 days on/4 days off 21 day treatment cycle. Only patients who had tumor imaging evaluation at least one month before the onset of the experimental treatment, a baseline tumor imaging, and at least one tumor evaluation after 2 cycles of treatment were eligible. Patient consent was obtained prior to analysis. We computed the TGR across the pre- (REFERENCE) and post-treatment (EXPERIMENTAL) evaluation, as described by Ferté et al (Clin Cancer Res, 2013) and compared these results to RECIST-based response evaluation. Each patient was used as his/her own control.Results: A total of twelve patients were eligible for both RECIST and TGR evaluation. At the time of first evaluation, 9 patients were classified as progressive disease (PD) and 3 as stable disease (SD) using RECIST. Conversely, TGR decreased in 6 out of 12 patients (median: - 9.8 %; CI 95% - 27.4 to 2.3), suggesting antitumor activity by the investigational drug. However, these 6 patients were classified as PD due to the occurrence of new lesions and then discontinued from the trial. They had small cell lung, colorectal, thymic, and bladder cancer. Interestingly, two patients suffering from ovary adenocarcinoma with durable SD (10 treatment cycles) had almost no tumor growth rate change between the REFERENCE and the EXPERIMENTAL period, suggesting no anti-tumor activity, and could potentially have been discontinued earlier from the trial. Conclusion: Computing the variation of TGR in the context of a phase 1 trial investigating a pan-CDK inhibitor reveals early signs of antitumor activity in specific patients, not previously identified by RECIST. Its use to guide the “go/no go” decision-making in the early drug development context is promising. Citation Format: Antoine Hollebecque, Charles Ferte, Gerard Nitenberg, Mathieu Felices, Alexandre Durand-Salmon, Matthias Ocker, Jean-Charles Soria. Computing tumor growth rate across pre- and post-treatment periods uncovers anti-tumor activity in patients treated by a pan-CDK inhibitor (BAY1000394). [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 900. doi:10.1158/1538-7445.AM2014-900
Abstract P231: Uric Acid Is Associated with Metabolic Syndrome in Children and Adults: The Bogalusa Heart Study
Authors: Dianjianyi Sun, Xiaotao Zhang, Shengxu Li, Camilo Fernandez, Wei Chen, Sathanur R Srinivasan, Gerald S Berenson
Journal: Circulation (2014)

Background: Elevated serum uric acid (UA) is commonly found in subjects with metabolic syndrome (MetS). This study assessed the hypothesis that UA is associated with levels of individual MetS components and the degree of their clustering patterns in different age periods. Methods: The study sample consisted of 2614 children (1577 whites, 1037 blacks; 1333 males; aged 4-18 years) and 2447 adults (1682 whites, 1765 blacks; 1072 males; aged 19-54 years) examined during 1987-2010. The adverse levels of MetS components, including body mass index (BMI), mean arterial pressure (MAP), triglycerides to HDL cholesterol ratio (TG/HDLC), and homeostasis model assessment of insulin resistance (HOMA), were defined as &gt;75th percentile specific for age, race and sex. Observed/expected (O/E) ratio and intra-class correlation (ICC) were used as a measure of the degree of clustering of categorical and continuous variables, respectively. Results: UA was significantly positively associated with only BMI in children, and with all four components in adults. Odds ratios of UA associated with MetS were 1.74 in children and 1.92 in adults (p&lt;0.001 for both), adjusted for race, sex and age. Trends in O/E ratios with UA quartiles are shown in the figure below. ICCs of 3- and 4-component clusters increased with increasing UA quartiles in children; however, only BMI-MAP-HOMA cluster showed an increasing trend of ICC in adults. Conclusions: The results suggest an important role of UA in the development of MetS in pediatric and adult populations. The findings provide further insights into the potential pathophysiological mechanisms of MetS and have implications for identification and treatment of high risk individuals for MetS in early life.
The Laboratory in Clinical Medicine. Interpretation and Application.
Authors: James A. Halsted, Charles H. Halsted
Journal: Annals of Internal Medicine (1977)

Details the most efficient way to use the clinical laboratory. Includes information on what kinds of tests to order, and how to get the most out of test results. Chapters cover infectious diseases, clinical nutrition, neoplastic diseases, pulmonary diseases, diseases of the heart, gastrointestinal disorders, diseases of the liver, renal diseases and hypertension, and hematologic disorders.
Analysis of <i>TGM1, ALOX12B, ALOXE3, NIPAL4</i> and <i>CYP4F22</i> in autosomal recessive congenital ichthyosis from Galicia (NW Spain): evidence of founder effects
Authors: L. Rodríguez‐Pazos, M. Ginarte, L. Fachal, J. Toribio, A. Carracedo, A. Vega
Journal: British Journal of Dermatology (2011)

Mutations in six genes have been identified in autosomal recessive congenital ichthyosis (ARCI). To date, few studies have analysed the spectrum of these mutations in specific populations.We have studied the characteristics of patients with ARCI in Galicia (NW Spain). Methods We recruited patients by contacting all dermatology departments of Galicia and the Spanish patient organization for ichthyosis. TGM1, ALOX12B, ALOXE3, NIPAL4 and CYP4F22 were analysed in the patients and their relatives.We identified 23 patients with ARCI and estimated a prevalence of 1 : 122 000. Twenty of the patients were studied. Seventeen of them were clinically categorized as having lamellar ichthyosis (LI) and three as having congenital ichthyosiform erythroderma (CIE). TGM1 and ALOXE3 mutations were identified in 12/16 (75%) probands whereas no ALOX12B, NIPAL4 and CYP4F22 mutations were found. TGM1 mutations were found in 11/13 (85%) of LI probands. ALOXE3 mutations were identified in a single patient with CIE. Remarkably, mutations p.Arg760X, p.Asp408ValfsX21 and c.984+1G>A of TGM1 were present in six, four and two families, accounting for 41%, 23% and 14% of all TGM1 mutant alleles, respectively.The high percentage of patients with the same TGM1 mutations, together with the high number of homozygous probands (64%), indicates the existence of a strong founder effect in our population.
The incidence of adverse reactions in anti-tuberculosis chemotherapy in S-W Romania
Authors: Emilian Damian Popovici, Voicu Tudorache, Luminita Mirela Baditoiu, Monica Licker, Marinela Gabriela Popovici, Ion Epure, Oana Florea, Daniel Viorel Tremurici
Journal: European Respiratory Journal (2011)

Introduction:  Although anti-tuberculosis chemotherapy is the fundamental therapeutic element, it is also accompanied by significant, sometimes potentially lethal adverse reactions.   Aims and objectives:  This study aims to determine the incidence of the main adverse reactions to anti-tuberculosis chemotherapy among patients diagnosed with active tuberculosis, HIV negatives, in S-W Romania.   Methods:  The descriptive, cross-sectional, retrospective study was performed by investigating the observation sheets of all 1,138 cases hospitalized with this diagnosis in the Clinical Hospital of Infectious Diseases and Pneumophtisiology, Timisoara, between 01.01.2008-31.12.2010.  The statistical processing was performed using the EPI-INFO vers. 6.04, the dichotomous variables being analysed using the hi 2  test and the Fisher correction.   Results:  A sample was identified consisting of 78 cases (age average: 46.10 years) with adverse effects occurring, on average, after 9.38 days of anti-tuberculosis treatment. The incidence remained constant – 5.92% in 2008 [95% confidence interval (95% CI): 3.56-8.28%], 7.84% in 2009 [95% CI: 4.93-10.71%], and 6.89% in 2010 [95% CI: 4.42-9.37%]. Most occurrences were among new cases (69.23% vs. 30.77%, p    Conclusions:  The constant incidence of adverse reactions to anti-tuberculosis chemotherapy during the 3 consecutive years studied, among new cases as well as relapses, require rigorous patient monitoring and treatment customization, so as to minimize the therapy drop-out risk.